Literature DB >> 7948750

The human interferon alpha-receptor protein confers differential responses to human interferon-beta versus interferon-alpha subtypes in mouse and hamster cell transfectants.

C Abramovich1, J Chebath, M Revel.   

Abstract

The human interferon alpha-receptor (IFNAR gene product or IFN alpha R protein) was expressed in hamster CHO cells and in mouse A9 cells. The response of the IFN alpha R cDNA transfectants to human IFNs was studied by measuring induction of (2'-5') A synthetase (2'-5' AS). In the murine cells, the IFN alpha R protein conferred response to the human IFN-alpha-8 (alpha-B) subtype, but not to huIFN-alpha-2 (alpha-A) or to huIFN-beta. In murine huIFN alpha R cDNA transfectants, containing a hygromycin B resistance gene placed under the control of the 2'-5' AS gene Interferon Response Sequence (IRS), survival and growth of the cells in the presence of hygromycin B was induced by huIFN-alpha-8 but not by huIFN-alpha-2, indicating that the effect of huIFN alpha R is transcriptional. In hamster CHO cells, the huIFN alpha R protein conferred a completely different pattern of response to human IFN subtypes. Thus, the CHO-IFN alpha R transfectants responded to huIFN-beta by 2'-5' AS induction as well as by activation of the ISGF3 and IRF-1 transcription factors. In contrast, the CHO-IFN alpha R cells showed no response to huIFN-alpha-8. The differential response conferred by the huIFN alpha R protein in the two types of rodent cells, indicates that IFN subtype recognition is influenced by another component contributed by the rodent host cell. The ability of human cells, and of human-mouse hybrid cells containing human chromosome 21, to respond to all IFN subtypes is likely to depend also on interactions of the IFN alpha R protein with additional receptor components.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7948750     DOI: 10.1016/1043-4666(94)90066-3

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon.

Authors:  R Deonarain; A Alcamí; M Alexiou; M J Dallman; D R Gewert; A C Porter
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice.

Authors:  X Q Qin; N Tao; A Dergay; P Moy; S Fawell; A Davis; J M Wilson; J Barsoum
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

3.  Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.

Authors:  Diego A Jaitin; Laila C Roisman; Eva Jaks; Martynas Gavutis; Jacob Piehler; Jose Van der Heyden; Gilles Uze; Gideon Schreiber
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

4.  Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling.

Authors:  Stephan Wilmes; Oliver Beutel; Zhi Li; Véronique Francois-Newton; Christian P Richter; Dennis Janning; Cindy Kroll; Patrizia Hanhart; Katharina Hötte; Changjiang You; Gilles Uzé; Sandra Pellegrini; Jacob Piehler
Journal:  J Cell Biol       Date:  2015-05-25       Impact factor: 10.539

5.  Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis.

Authors:  Rana Khsheibun; Tamar Paperna; Anat Volkowich; Izabella Lejbkowicz; Nili Avidan; Ariel Miller
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

6.  Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta.

Authors:  C Abramovich; L M Shulman; E Ratovitski; S Harroch; M Tovey; P Eid; M Revel
Journal:  EMBO J       Date:  1994-12-15       Impact factor: 11.598

7.  Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer.

Authors:  M Ohashi; K Yoshida; M Kushida; Y Miura; S Ohnami; Y Ikarashi; Y Kitade; T Yoshida; K Aoki
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.